Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?

Nat Clin Pract Oncol. 2005 Feb;2(2):68-9. doi: 10.1038/ncponc0080.
No abstract available

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology*
  • Aged
  • Antineoplastic Agents, Hormonal / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Docetaxel
  • Drug Resistance, Neoplasm
  • Humans
  • Male
  • Mitoxantrone / administration & dosage
  • Prednisone / administration & dosage
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology*
  • Survival Analysis
  • Taxoids / administration & dosage
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal
  • Taxoids
  • Docetaxel
  • Mitoxantrone
  • Prednisone